伊曲康唑胶囊与依非韦伦在HIV合并播散性马尔尼菲篮状菌病治疗中的药物相互作用
一项开放标签、单臂、序贯药代动力学研究,纳入10例HIV合并马尔尼菲篮状菌病成人患者,评估伊曲康唑胶囊及其活性代谢物羟基伊曲康唑与依非韦伦的相互作用。结果显示,联用依非韦伦后伊曲康唑和羟基伊曲康唑的AUC0-12分别平均降低86%和84%,伊曲康唑谷浓度低于推荐治疗水平。
要点
- 依非韦伦显著降低伊曲康唑胶囊及其代谢物暴露,AUC降幅达84%-86%。
- 联用依非韦伦时伊曲康唑谷浓度低于0.5 μg/mL的治疗阈值。
- 该相互作用的临床影响需进一步评估。
核心结论
- 依非韦伦与伊曲康唑胶囊联用显著降低伊曲康唑和羟基伊曲康唑的暴露。
- 该药物相互作用对马尔尼菲篮状菌病治疗或预防的临床影响尚需进一步评估。
研究设计与样本
- 开放标签、单臂、序贯药代动力学研究。
- 纳入10例确诊马尔尼菲篮状菌病、计划启动依非韦伦为基础抗逆转录病毒治疗的HIV成人患者。
- 在未用和联用依非韦伦时分别进行稳态药代动力学评估(给药前及给药后1、3、4、5、6、8、12小时采血)。
- 同时评估依非韦伦中位剂量浓度。
- 药代动力学参数采用非房室分析计算。
主要发现
- 入组时中位年龄29.5岁(范围22-64),中位CD4细胞计数18.0 cells/mm3(范围1-39)。
- 羟基伊曲康唑与伊曲康唑中位代谢比(95%CI)为1.3(0.9-1.9)。
- 联用依非韦伦后,伊曲康唑和羟基伊曲康唑AUC0-12平均分别降低86%(71%-94%)和84%(64%-97%)。
- 联用依非韦伦时伊曲康唑谷浓度低于推荐治疗水平0.5 μg/mL,所有受试者依非韦伦中位剂量浓度>1000 ng/mL。
临床怎么用
- HIV合并马尔尼菲篮状菌病患者使用依非韦伦为基础方案时,需警惕伊曲康唑胶囊暴露显著下降。
- 联用依非韦伦时伊曲康唑谷浓度可能低于0.5 μg/mL的治疗水平,需考虑治疗药物监测或调整方案。
局限性
- 样本量小(10例),结果外推需谨慎。
- 单臂、序贯设计,未设对照臂。
- 临床结局(治疗或预防效果)未在本研究中评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the pharmacokinetic of itraconazole capsule formulation and its active metabolite, hydroxyitraconazole, in adults with HIV diagnosed with talaromycosis in an endemic area, and to evaluate the drug-drug interaction between itraconazole/hydroxyitraconazole (ITC/OH-ITC) and efavirenz. METHODS: Open-label, single arm, sequential pharmacokinetic study. Eligible subjects were adults with HIV, ≥18 years old, with confirmed talaromycosis, initiating itraconazole capsule as part of standard talaromycosis treatment, in whom efavirenz-based ART was anticipated. Steady-state pharmacokinetic assessments (pre-dose and at 1, 3, 4, 5, 6, 8 and 12 h post dose) were performed for itraconazole/hydroxyitraconazole without and with efavirenz use. Mid-dose efavirenz concentrations were also assessed. Pharmacokinetics parameters were calculated using non-compartmental analysis. RESULTS: Ten subjects (70% male) were enrolled. At entry, median (range) age was 29.5 years (22-64), and CD4 cell count was 18.0 (1-39) cells/mm3. Geometric mean (95% CI) of itraconazole and hydroxyitraconazole AUC0-12 without efavirenz were 9097 (6761-12 239) and 11 705 (8586-15 959) ng·h/mL, respectively, with a median metabolic ratio of OH-ITC : ITC of 1.3 (95% CI 0.9-1.9). Intra-subject comparison revealed that both itraconazole and hydroxyitraconazole exposures were significantly reduced with concomitant efavirenz use, with the mean AUC0-12 of itraconazole and hydroxyitraconazole being 86% (71%-94%) and 84% (64%-97%) lower, respectively. With efavirenz, itraconazole trough concentrations were also below the recommended therapeutic level (0.5 μg/mL). All subjects had mid-dose efavirenz concentrations >1000 ng/mL. CONCLUSIONS: Concomitant administration of itraconazole capsule with efavirenz significantly reduced itraconazole and hydroxyitraconazole exposures. The clinical impact of this drug-drug interaction on talaromycosis treatment or prophylaxis in the era of potent ART needs further evaluation.
引用
- Kaewpoowat Q, Chaiwarith R, Yasri S, et al. Drug-drug interaction between itraconazole capsule and efavirenz in adults with HIV for talaromycosis treatment. J Antimicrob Chemother. 2021. PMID: 33349869. doi:10.1093/jac/dkaa521
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。